Go Pro
→ The world’s least risky AI stock? (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$227.12
+1.4%		$274.35
$197.81
▼
$495.55
$29.97B0.32.24 million shs1.45 million shs
Biogen Inc. stock logo
BIIB
Biogen
$210.65
+0.9%		$203.47
$131.52
▼
$219.72
$30.86B0.171.06 million shs860,079 shs
Insmed, Inc. stock logo
INSM
Insmed
$126.33
-4.5%		$107.29
$90.39
▼
$212.75
$28.89B0.813.23 million shs2.48 million shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$58.86
-1.3%		$54.73
$29.87
▼
$65.00
$8.88B1.23995,145 shs839,077 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
+1.42%+5.09%-19.25%-20.86%-47.49%
Biogen Inc. stock logo
BIIB
Biogen
+0.85%+2.12%+9.74%+9.17%+55.80%
Insmed, Inc. stock logo
INSM
Insmed
-4.50%-4.69%+14.73%+15.75%+2.82%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-1.32%-0.05%+4.71%+12.35%+86.56%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$227.12
+1.4%		$274.35
$197.81
▼
$495.55
$29.97B0.32.24 million shs1.45 million shs
Biogen Inc. stock logo
BIIB
Biogen
$210.65
+0.9%		$203.47
$131.52
▼
$219.72
$30.86B0.171.06 million shs860,079 shs
Insmed, Inc. stock logo
INSM
Insmed
$126.33
-4.5%		$107.29
$90.39
▼
$212.75
$28.89B0.813.23 million shs2.48 million shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$58.86
-1.3%		$54.73
$29.87
▼
$65.00
$8.88B1.23995,145 shs839,077 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
+1.42%+5.09%-19.25%-20.86%-47.49%
Biogen Inc. stock logo
BIIB
Biogen
+0.85%+2.12%+9.74%+9.17%+55.80%
Insmed, Inc. stock logo
INSM
Insmed
-4.50%-4.69%+14.73%+15.75%+2.82%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-1.32%-0.05%+4.71%+12.35%+86.56%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2.92
Moderate Buy$396.7274.67% Upside
Biogen Inc. stock logo
BIIB
Biogen
2.58
Moderate Buy$227.077.80% Upside
Insmed, Inc. stock logo
INSM
Insmed
3.00
Buy$205.5262.69% Upside
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
2.38
Hold$86.0046.11% Upside

Current Analyst Ratings Breakdown

Latest PCVX, BIIB, ALNY, and INSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2026
Biogen Inc. stock logo
BIIB
Biogen
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$300.00
8/10/2026
Insmed, Inc. stock logo
INSM
Insmed
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$185.00 ➝ $195.00
8/10/2026
Insmed, Inc. stock logo
INSM
Insmed
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/10/2026
Insmed, Inc. stock logo
INSM
Insmed
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$179.00 ➝ $175.00
8/7/2026
Insmed, Inc. stock logo
INSM
Insmed
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$218.00
8/7/2026
Insmed, Inc. stock logo
INSM
Insmed
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$170.00
8/7/2026
Insmed, Inc. stock logo
INSM
Insmed
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$207.00 ➝ $205.00
8/7/2026
Insmed, Inc. stock logo
INSM
Insmed
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$172.00
8/7/2026
Insmed, Inc. stock logo
INSM
Insmed
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$161.00 ➝ $169.00
8/6/2026
Insmed, Inc. stock logo
INSM
Insmed
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$175.00
8/4/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$410.00 ➝ $315.00
(Data available from 8/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$4.80B6.33$2.84 per share80.09$10.12 per share22.44
Biogen Inc. stock logo
BIIB
Biogen
$10.03B3.10$22.82 per share9.23$127.56 per share1.65
Insmed, Inc. stock logo
INSM
Insmed
$606.42M45.49N/AN/A$3.47 per share36.41
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$18.53 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$313.75M$5.3842.2223.54N/A15.26%84.93%14.30%10/29/2026 (Estimated)
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$5.6537.2812.856.458.32%11.18%6.88%10/29/2026 (Estimated)
Insmed, Inc. stock logo
INSM
Insmed
-$1.28B-$4.11N/A48.40N/A-76.94%-123.94%-44.30%10/29/2026 (Estimated)
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$766.63M-$7.63N/AN/AN/AN/A-37.56%-33.62%N/A

Latest PCVX, BIIB, ALNY, and INSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Insmed, Inc. stock logo
INSM
Insmed
-$0.6724-$0.06+$0.6124-$0.06$395.50 million$425.49 million
8/5/2026Q2 2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$2.06-$1.97+$0.09-$1.97$12.50 millionN/A
7/29/2026Q2 2026
Biogen Inc. stock logo
BIIB
Biogen
$2.94$3.60+$0.66$0.66$2.46 billion$2.74 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/AN/AN/AN/AN/A
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.75
3.05
2.99
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.87
1.26
Insmed, Inc. stock logo
INSM
Insmed
0.74
3.72
3.40
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
5.72
5.72

Institutional Ownership

CompanyInstitutional Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
92.97%
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Insmed, Inc. stock logo
INSM
Insmed
N/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%

Insider Ownership

CompanyInsider Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.86%
Biogen Inc. stock logo
BIIB
Biogen
0.25%
Insmed, Inc. stock logo
INSM
Insmed
2.10%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2,770133.81 million132.66 millionOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.75 million147.39 millionOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,664218.38 million213.80 millionOptionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
160148.80 million143.89 millionOptionable

Recent News About These Companies

Assenagon Asset Management S.A. Decreases Stock Holdings in Vaxcyte, Inc. $PCVX
August 12 at 3:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-assenagon-asset-management-sa-decreases-stock-holdings-in-vaxcyte-inc-pcvx-2026-08-12/
Bank of America Corp DE Increases Position in Vaxcyte, Inc. $PCVX
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-increases-position-in-vaxcyte-inc-pcvx-2026-08-10/
Vaxcyte (NASDAQ:PCVX) Upgraded to "Sell" at Wall Street Zen
August 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30947826
Vaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Wall Street Zen
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vaxcyte-nasdaqpcvx-stock-rating-upgraded-by-wall-street-zen-2026-08-08/
Analysts Offer Insights on Healthcare Companies: Vaxcyte (PCVX), Black Diamond Therapeutics (BDTX) and Sarepta Therapeutics (SRPT)
August 7, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PCVX/pressreleases/3714550/analysts-offer-insights-on-healthcare-companies-vaxcyte-pcvx-black-diamond-therapeutics-bdtx-and-sarepta-therapeutics-srpt/
Vaxcyte (PCVX) Receives a Buy from Guggenheim
August 7, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PCVX/pressreleases/3715307/vaxcyte-pcvx-receives-a-buy-from-guggenheim/
The Manufacturers Life Insurance Company Trims Stock Position in Vaxcyte, Inc. $PCVX
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-the-manufacturers-life-insurance-company-trims-stock-position-in-vaxcyte-inc-pcvx-2026-08-07/
Vaxcyte, Inc. $PCVX Shares Acquired by Dimensional Fund Advisors LP
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vaxcyte-inc-pcvx-shares-acquired-by-dimensional-fund-advisors-lp-2026-08-07/
Insider Selling: Vaxcyte (NASDAQ:PCVX) COO Sells 2,250 Shares
August 6, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-pcvx-insider-buying-and-selling-2026-08-06/
Vaxcyte (NASDAQ:PCVX) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vaxcyte-nasdaqpcvx-releases-quarterly-earnings-results-beats-expectations-by-009-eps-2026-08-05/
Vaxcyte (NASDAQ:PCVX) Insider Harpreet Dhaliwal Sells 17,000 Shares
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vaxcyte-nasdaqpcvx-insider-harpreet-dhaliwal-sells-17000-shares-2026-08-05/
Insider Selling: Vaxcyte (NASDAQ:PCVX) COO Sells 2,250 Shares of Stock
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-vaxcyte-nasdaqpcvx-coo-sells-2250-shares-of-stock-2026-08-05/
Vaxcyte (NASDAQ:PCVX) CFO Andrew Guggenhime Sells 10,000 Shares of Stock
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vaxcyte-nasdaqpcvx-cfo-andrew-guggenhime-sells-10000-shares-of-stock-2026-08-05/
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
August 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/05/3339693/0/en/vaxcyte-reports-second-quarter-2026-financial-results-and-provides-business-update.html
California State Teachers Retirement System Has $7.91 Million Holdings in Vaxcyte, Inc. $PCVX
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-has-791-million-holdings-in-vaxcyte-inc-pcvx-2026-08-05/
Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Hold" by Brokerages
August 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30939221
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Recommendation of "Hold" from Analysts
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vaxcyte-inc-nasdaqpcvx-receives-consensus-recommendation-of-hold-from-analysts-2026-08-04/
Seven Fleet Capital Management LP Buys 103,085 Shares of Vaxcyte, Inc. $PCVX
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-seven-fleet-capital-management-lp-buys-103085-shares-of-vaxcyte-inc-pcvx-2026-08-02/
DV Trading LLC Takes Position in Vaxcyte, Inc. $PCVX
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-dv-trading-llc-takes-position-in-vaxcyte-inc-pcvx-2026-08-02/
Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (GEHC), Biogen (BIIB) and Vaxcyte (PCVX)
July 31, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/BIIB-Q/pressreleases/3572153/analysts-offer-insights-on-healthcare-companies-ge-healthcare-technologies-inc-gehc-biogen-biib-and-vaxcyte-pcvx/
Vaxcyte Inc : pcvx
July 30, 2026  |  247wallst.comhttps://247wallst.com/companies/pcvx/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alnylam Pharmaceuticals stock logo

Alnylam Pharmaceuticals NASDAQ:ALNY

$227.12 +3.17 (+1.42%)
Closing price 08/13/2026 04:00 PM Eastern
Extended Trading
$228.46 +1.34 (+0.59%)
As of 08/13/2026 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen stock logo

Biogen NASDAQ:BIIB

$210.65 +1.78 (+0.85%)
Closing price 08/13/2026 04:00 PM Eastern
Extended Trading
$210.07 -0.58 (-0.27%)
As of 08/13/2026 06:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Insmed stock logo

Insmed NASDAQ:INSM

$126.33 -5.95 (-4.50%)
Closing price 08/13/2026 04:00 PM Eastern
Extended Trading
$126.50 +0.17 (+0.13%)
As of 08/13/2026 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$58.86 -0.79 (-1.32%)
Closing price 08/13/2026 04:00 PM Eastern
Extended Trading
$58.90 +0.05 (+0.08%)
As of 08/13/2026 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas